Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics
Today's Latest Price: $1.65 USD
Nov 27 1:00pm Add ABEO to Watchlist Sign Up
ABEO Stock Summary The capital turnover (annual revenue relative to shareholder's equity) for ABEO is -0.02 -- better than only 6.6% of US stocks. ABEO's went public 34.25 years ago, making it older than 92.52% of listed US stocks we're tracking. Revenue growth over the past 12 months for Abeona Therapeutics Inc comes in at -139.84%, a number that bests merely 0.35% of the US stocks we're tracking. Stocks that are quantitatively similar to ABEO, based on their financial statements, market capitalization, and price volatility, are HTBX, CRIS, ALBO, ADRO, and VTVT. ABEO's SEC filings can be seen here. And to visit Abeona Therapeutics Inc's official web site, go to www.abeonatherapeutics.com.
ABEO Price/Volume Stats
Abeona Therapeutics Inc. (ABEO) Company Bio
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.
ABEO Latest News Stream
All News Types
Commentary Debt Offering Earnings Mgmt Change New Coverage (Bullish) Options Product News PT Raised Resumes Coverage (Bullish) Stock Offering
Loading, please wait...
Latest ABEO News From Around the Web
Below are the latest news stories about Abeona Therapeutics Inc that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
B.Riley initiated Abeona Therapeutics ([[ABEO]] +12.2%) with a Buy rating, PT $5 indicating a more than double upside from current levels.Analyst Justin Zelin believes that the company is now positioned to potentially have three rare disease approvals by 2023.Quick look at its robust pipeline:Led by balance sheet concerns, management turnover,...
The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this event....
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS…
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands.
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
Read More 'ABEO' Stories Here
ABEO Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7852 seconds.